SG Americas Securities LLC Purchases 2,014 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

SG Americas Securities LLC lifted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 27.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,369 shares of the biotechnology company’s stock after buying an additional 2,014 shares during the quarter. SG Americas Securities LLC’s holdings in Arrowhead Pharmaceuticals were worth $244,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Neo Ivy Capital Management acquired a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $41,000. Quest Partners LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth about $45,000. Headlands Technologies LLC boosted its stake in Arrowhead Pharmaceuticals by 7,696.8% during the 1st quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 2,386 shares during the period. Van ECK Associates Corp boosted its stake in Arrowhead Pharmaceuticals by 22.9% during the 4th quarter. Van ECK Associates Corp now owns 2,395 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 447 shares during the period. Finally, Ontario Teachers Pension Plan Board acquired a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $201,000. 62.61% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on ARWR. Morgan Stanley cut their price target on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating for the company in a report on Monday, May 13th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 23rd. Cantor Fitzgerald restated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Thursday, June 20th. B. Riley reiterated a “buy” rating and issued a $55.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 12th. Finally, StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $44.25.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, insider Tracie Oliver sold 9,394 shares of the business’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $25.28, for a total value of $237,480.32. Following the sale, the insider now owns 127,107 shares in the company, valued at approximately $3,213,264.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.50% of the company’s stock.

Arrowhead Pharmaceuticals Stock Up 1.7 %

NASDAQ ARWR opened at $24.78 on Friday. The stock has a market cap of $3.08 billion, a P/E ratio of -5.83 and a beta of 0.94. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $20.67 and a twelve month high of $39.83. The company’s 50-day simple moving average is $26.01 and its 200 day simple moving average is $26.60.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.80). Arrowhead Pharmaceuticals had a negative return on equity of 140.72% and a negative net margin of 163.32%. The company’s quarterly revenue was down 100.0% on a year-over-year basis. During the same period last year, the firm earned ($0.96) earnings per share. Research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.04 earnings per share for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.